LONDON, December 2 - In 2002 the National Institute for Clinical Excellence (NICE) ruled that certain drugs for the treatment of Multiple Sclerosis were not cost effective. In response, the Department of Health (DH) set up an observational study called the Risk Sharing Scheme. The aim of the study was to observe the effects of these drugs (over a10 year period) and if the 4 drugs in question failed to perform as promised then the manufacturers would share the risk of any potential negative outcomes by subsidising their future cost to the NHS. The scheme promised to make these drugs available to all those with MS who fitted the study criteria.

ATHENS, Greece, December 1 - The Invest in Greece Agency, in collaboration with the Greek Embassy in Australia, is organizing Investment Forums in Australia from December 3rd until December 9th, to present investment opportunities in Greece in the sectors of Financial Services, Tourism, Renewable Energy and Information Technology.

STOCKHOLM, December 1 - GpsGate has released GpsGate VehicleTracker 2.3, a web based GPS tracking application for transportation companies and tracking solution providers. This version adds a redesigned user interface for improved operator efficiency, configurable system alerts for immediate email and SMS notifications and a mobile application interface for managers working in the field.

NEWNAN, Georgia, December 1 - CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that Barry Katzen, MD, FACR, FACC, FSCAI, founder and medical director of Baptist Cardiac & Vascular Institute in Miami, Florida, will discuss the CATANIA(TM) Stent System with NanoThin Polyzene(R)-F at the Innovations in Cardiovascular Interventions Conference to be held at the Hotel David InterContinental in Tel Aviv, Israel, which will include new information about the stent's coating, Polyzene(R)-F, and clinical outcomes in coronary, below-the-knee, and neurovascular applications. "We are deeply honored that Dr. Katzen will present these data at the ICI conference where innovation is recognized and celebrated. We believe the CATANIA(TM) stent is the technological breakthrough that interventional cardiologists have needed to dispense with the problems associated with bare metal and drug-eluting stents," said Thomas A. Gordy, President and chief Executive Officer of CeloNova. "Dr. Katzen is a true pioneer in interventional medicine."

NEWNAN, Georgia, December 1 - CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that President and Chief Executive Officer, Thomas A. Gordy, will give an opening address for the Technology Parade at the Innovations in Cardiovascular Interventions Conference in Tel Aviv, Israel. "We must leave the era of petty self-interest behind and focus the rich intellectual resources of the health care industry toward collaboration, innovation, and rapid market entry. We need more heart, more passion, and more integrity. With laser-like focus, we can truly heal the world," said Gordy. "The international faculty at ICI is renowned for spotlighting transformative technology."